Studies have indicated an altered distribution of circulating ILC subsets in SLE patients.87,88 Given their recognized involvement in autoimmune disease pathogenesis, researchers have suggested the potential of ILCs as therapeutic targets.89 Evidence from preclinical and experimental animal models suggests the participation of ILCs in various autoimmune diseases, including SLE.90 However, further investigation is necessary before considering ILCs as candidates for cell therapy in SLE. Here, CCL27 is linked to systemic lupus erythematosus.